Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

NCT06529549 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

OTHER: Organoid-Based Drug Sensitivity Screening

Sponsor

Sun Yat-sen University